Following President Trump’s announcement on Monday of an executive order to cut prescription drug prices, experts share some ...

but the sheer size of Humira makes that a tough task. Newer products such as blood cancer drug Imbruvica (ibrutinib) – which brought in almost $3 billion last year – and hepatitis C virus ...

Tom Speight, showing off his gym-honed physique, looked every inch the confident pop star as the photographer snapped away.

Nonetheless, the pricing of Humira biosimilars from Sandoz ... for its C-met-targeting lung cancer ADC Emrelis.

Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big ...

Coherus BioSciences, Inc.’s CHRS share price has surged by 6.25%, which has investors questioning if this is right time to sell.

Squeezed by insurers and middlemen, independent pharmacists such as Jolley find themselves on the front lines of a tariff ...

While Big Pharma seems ready to weather the tariff storm, independent pharmacists and makers of generic drugs — which account ...

Slow progress, pipeline uncertainty & lack of catalysts weigh despite strong cash. Click to read why KYMR stock is a Hold.

Trading in the Company’s SDRs on Nasdaq Stockholm commences on Monday, May 19, 2025, under the trading symbol (ticker) “ALVO SDB”. Settlement is expected to take place on May 21, 2025.